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Summary The influence of tamoxifen on plasma lipids and lipoproteins was monitored in 46 postmeno-
pausal and 8 premenopausal women treated for advanced breast cancer up till 6 months. Total cholesterol
(total-C) did not significantly change. However, high density lipoprotein cholesterol (HDL-C) and the HDL-C/
total-C ratio rose significantly. Low density lipoprotein cholesterol was significantly decreased. Triglycerides
and free fatty acids did not change markedly. The concomitant rise of sex hormone binding globulin and
thyroxine binding globulin indicates that the increase of HDL-C with prolonged use of tamoxifen is
compatible with an intrinsic oestrogenic effect of tamoxifen on the liver. The increased HDL-C/total-C ratio
lends no support to the concern that long-term administration of this anti-oestrogenic drug might lead to an
increased cardiovascular risk.
Treatment with tamoxifen is now widely accepted as the
first-line endocrine treatment of choice in advanced breast
cancer. Objective tumour responses are seen in some 30% of
all cases in pre- and postmenopausal patients. The mean
duration of tumour remission is 11 to 12 months, but
responses lasting a few years are no exception (Mouridsen et
al., 1978).
In some countries tamoxifen is also prescribed for benign
breast conditions, generally to premenopausal women and
often for periods longer than one year. The use of tamoxifen
as an adjuvant after curative treatment for primary breast
cancer is currently widely employed. As reported recently
(Anonymous, 1987), at least forty-two randomised trials
assessing adjuvant tamoxifen have been identified. Most
trials concern postmenopausal patients having axillary node
metastasis, but results from the Scottish trial showed a
highly significant delay in relapse in the tamoxifen treated
patients compared to the control arm patients, irrespective of
menopausal or nodal status (Anonymous, 1987). The op-
timal duration of adjuvant tamoxifen treatment is not yet
known, but may be at least 5 years or even life-long. The
success of adjuvant therapy has already elicited proposals for
prevention trials in women carrying a high risk of developing
breast cancer (Cuzick et al., 1986). Tamoxifen has very few
clinical side-effects of which hardly any is serious enough to
urge its withdrawal. However, very little is known about
possible long-term toxicity. One undesired long-term effect
might be a reduction of the protection from cardiovascular
disease, which women owe to their sex, most likely due to
oestrogenic hormones (Gordon et al., 1978; Rosenberg et al.,
1981; Wilson et al., 1987).
There is no doubt that the serum level of total cholesterol
(total-C) which is mainly determined by low density lipo-
protein cholesterol (LDL-C), ranks, along with cigarette
smoking and hypertension, as one of the three major risk
factors for coronary heart disease (Levy, 1983). The serum
level of high density lipoprotein cholesterol (HDL-C) on the
other hand is an independent factor which is inversely
correlated with cardiovascular risk (Levy, 1981). A recent
position statement by the American Heart Association
underlined the importance of total-C and HDL-C as cardio-
vascular risk factors (Grundy et al., 1987).
A 20-year old follow-up study of coronary artery disease
in Israel has demonstrated that the HDL-C/total-C ratio is a
significant risk factor in men and women, both at high and
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low levels of total-C (ranging from more than 6.8mM to less
than 5.2mM) (Brunner et al., 1987). Serum lipoproteins are
influenced by sex hormones, estrogens causing an increase of
HDL (Krauss, 1982). It could be anticipated that the long-
term use of an anti-oestrogenic drug like tamoxifen might
entail a decrease of the HDL-C/total C ratio, and thereby
contribute to the risk of cardiovascular disease. We have
recently reported that prolonged administration to patients
with advanced breast cancer responsive to tamoxifen has not
caused any deterioration of the HDL-C/total C-ratio. On the
contrary, apparently due to its intrinsic oestrogenic activity,
tamoxifen resulted in an increase of HDL-C and a decrease
of LDL-C (Bruning et al., 1987).
Patients and methods
Eight premenopausal (mean age 43.3 +3.6yrs) and 46 post-
menopausal women (mean age 63.2 +9.5yrs) with advanced
breast cancer were treated with tamoxifen 10mg t.i.d. Blood
samples were collected after a 12 h fast, in dry lithium-
heparinized Vacutainer't glass tubes, early in the morning,
before treatment (to) and after 2 months of therapy (t2). In
the patients who responded to therapy (4 premenopausal and
31 postmenopausal) samples were also collected after 6
months (t6).
All patients were requested to fill in a questionnaire on
their smoking and drinking habits, and the concomitant use
of drugs, which could affect lipoprotein values. Patients with
diabetes mellitus or thyroid function abnormalities were not
eligible for the study.
Cholesterol and triglycerides (TG) were measured enzym-
atically with a test kit from Boehringer Diagnostica (Mann-
heim, W. Germany). HDL-C was measured in the
supernatant after precipitation of all other lipoproteins with
phosphotungistic acid and magnesiumchloride (Burstein et
al., 1970; Lopes-Virella, 1977). LDL-C was calculated
according to Friedewald et al. (1972). Free fatty acids (FFA)
were measured colorimetrically (Regouw et al., 1971). The
assays of oestrone, oestradiol, testosterone, thyrotropin
(TSH) and free thyroxine index have been described else-
where (Bruning et al., 1984).
Sex hormone binding globulin (SHBG) was measured with
an IRMA-kit from Farmos Diagnostica (Oulunsalo, Fin-
land). Changes in time and differences between pre- and
postmenopausal women were tested by two-way analysis of
variance. Based on normal probability plots, which were
made first for all data, the basic analysis was performed on
log-values.
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Results
In Tables I and II the results are shown for pre- and
postmenopausal patients, respectively, The mean log values
at to and t2, or to and t6, as well as the mean values
obtained by transformation from log to normal are pre-
sented. Total-C showed a trend to decrease, especially in the
premenopausal women. HDL-C did not change before 2
months, but was significantly increased after 6 months of
treatment both in pre- and postmenopausal patients. As a
result, the HDL-C/total-C ratio increased significantly after
6 months, irrespective of menopausal status. Interestingly, at
2 months there was a significant difference for HDL-C and
the HDL-C/total-C ratio in patients responding to tamoxifen
compared to non-responders. The latter showed a decreasing
HDL-C and a stable HDL-C/total-C ratio, whereas respond-
ing patients had stable HDL-C and increasing HDL-C/total-
C values. This difference for HDL-C (P=0.01) and HDL-C/
total-C ratio (P<0.05) was observed in both pre- and
postmenopausal women.
LDL-C significantly decreased already after 2 months,
both before and after menopause. TG and FFA did not
significantly change after 6 months. Only FFA levels rose
temporarily at 2 months (P<0.05) in both menopausal
groups. The premenopausal patients were bled at different
time points of their menstrual cycles which may have an
influence on the observed figures. Certainly, the number of
observed premenopausal steroid levels was too small for any
conclusion. Tamoxifen had no significant effect on the
plasma concentrations of postmenopausal oestrogens or
testosterone. However, SHBG was markedly increased after
2 and 6 months, pre- and postmenopausally.
Thyroid function remained stable, as indicated by the free
thyroxine index and clinical picture. However, at the same
time thyroxine levels rose significantly with a concomitant
drop of triiodothyroxine resin uptake (P<0.0001) and a
slight, but significant rise of TSH (P<0.05). These effects,
which are indicative of an increased level of thyroxine
binding globulin were already apparent at 2 months, and
persisted through 6 months in pre- and postmenopausal
patients alike.
Only 6 out of 54 women smoked cigarettes daily (average
19, range 10 to 25). None of the patients was an excessive
drinker of alcoholic beverages (daily average 0.3, range 0 to
3 drinks). These smoking and drinking habits did not seem
to change during the observation period. Most patients kept
the same body weight (mean 69.4+ 10.3 kg in responding
patients; 70.9+7.6kg in non-responding patients), although
there was a general trend to some weight gain.
Discussion
The beneficial effect of adjuvant tamoxifen treatment on
disease free survival and overall survival of breast cancer
patients (Anonymous, 1987) will massively expand its pro-
longed use in apparently healthy women. The high incidence
of breast cancer in the Western industrialized countries and
the favourable recent trend towards detection at an early
stage of the disease make, that a large number of women
will receive adjuvant tamoxifen therapy. Although the opti-
mum has not yet been defined, the drug should preferably be
administered during several years, if not life-long. The
advantages should be weighed against possible long-term
toxicity.
On the whole women are known to have a lower risk of
cardiovascular disease than men of comparable age. Various
studies demonstrated that this difference is greater before the
age of menopause and that premature ovarian ablation is
Table I Fasting plasma values in premenopausal women before and during treatment with tamoxifen
n=8 n=4
Before After 2 months Before After 6 months
Meana Mean log±s.e. Meana Mean log±s.e. Meana Mean log±s.e. Meana Mean log±s.e.
Total-C mm 5.2 0.71 +0.03 4.5 0.65+0.03c 5.7 0.76+0.03 5.3 0.73+0.03
HDL-C mM 1.2 0.07+0.03 1.2 0.09+0.04 1.1 0.04+0.06 1.3 0.11+0.07b
LDL-C mM 3.4 0.53+0.05 2.6 0.42+0.04d 3.9 0.59+0.06 3.2 0.51+0.03C
HDL-C/total-C 0.23 -0.65+0.06 0.27 -0.56+0.05 0.19 -0.72+0.09 0.24 -0.62+0.08c
FFA mm 0.39 -0.41+0.06 0.60 -0.22+0.07b 0.47 -0.33 +0.06 0.76 -0.12+0.04
TG mm 1.10 0.04+0.06 1.15 0.06+0.08 1.31 0.12+0.06 1.59 0.20+0.11
SHBG nM 43 1.64+0.03 61 1.78+0.04d 44 1.65+0.05 70 1.84+0.IOd
Thyroxine pugdl 8.8 0.94+0.03 9.7 0.98+0.04c 8.3 0.92+0.05 9.5 0.98+0.09c
Free thyroxine index 2.3 0.36+0.02 2.3 0.35+0.04 2.6 0.34+0.05 2.1 0.32+0.07
aAfter transformation from log to normal values; bp<0.05; Cp<0.01; d<0.0001.
Table II Fasting plasma values in postmenopausal women before and during treatment with tamoxifen
n=46 n=31
Before After 2 months Before After 6 months
Meana Mean log±s.e. Meana Mean log± s.e. Meana Mean log±s.e. Meana Mean log±s.e.
Total-C mm 5.8 0.77+0.01 5.7 0.76+0.01 6.0 0.77+0.01 5.6 0.75+0.01
HDL-C mM 1.3 0.10+0.02 1.2 0.08+0.02 1.3 0.10+0.02 1.4 0.13+0.03b
LDL-C mM 3.8 0.58+0.02 3.4 0.53+0.02d 3.9 0.59+0.02 3.4 0.53+0.02c
HDL-C/total-C 0.21 -0.67+0.02 0.21 -0.67+0.03 0.21 -0.67+0.02 0.24 -0.62+0.03c
FFA mm 0.57 -0.20+0.03 0.60 -0.22+0.02b 0.57 -0.24+0.04 0.61 -0.21+0.03
TG mM 1.55 0.19+0.03 1.86 0.27+0.03 1.46 0.16+0.03 1.57 0.20+0.03
SHBG nM 42 1.62+0.03 71 1.85+0.03d 41 1.61+0.05 72 1.86+0.04d
Oestradiol pM 41 1.62+0.03 42 1.62+0.04 42 1.63+0.04 50 1.70+0.05
Oestrone pM 132 2.12+0.02 144 2.16+0.03 132 2.12+0.03 130 2.11+0.03
Testosterone pM 1.02 0.01 +0.03 1.14 0.06+0.03 1.04 0.02+0.03 1.17 0.07+0.04
Thyroxine pgdl 8.6 0.93+0.01 9.4 0.97+0.01c 8.5 0.93+0.01 10.3 1.01+0.01c
Free thyroxine index 2.2 0.34+0.01 2.2 0.34+0.01 2.2 0.33+0.01 2.3 0.36+0.01
aAfter transformation from log to normal values; bp<O.05; cP<0.01; d<0.0001.TAMOXIFEN AND SERUM LIPOPROTEINS 499
related to an increase of cardiovascular risk (Wilson et al.,
1987; Gordon et al., 1978; Rosenberg et al., 1981). Other
studies have indicated that oral oestrogen replacement treat-
ment may reduce risk (Bain et al., 1981; Ross et al., 1981).
Unfortunately, as yet no prospective data on the long-term
use of tamoxifen and cardiovascular risk have been pub-
lished, or are likely to be available in the nearest future. It is
therefore reassuring that the results from the present study
do not show an adverse effect of prolonged anti-oestrogenic
treatment with tamoxifen on one of the three major risk
factors for coronary disease. Instead LDL-C is reduced and
HDL-C with its cholesterol scavenging properties, and the
HDL-C/total-C ratio appear to be significantly increased by
prolonged use of tamoxifen. This favourable result is com-
patible with the known fact that tamoxifen can exert some
oestrogenic activity (Patterson et al., 1982).
The increase of the high density lipoprotein cholesterol,sex
hormone binding globulin and, as demonstrated in-
directly in this study, of thyroxine binding globulin in plasma
suggests that tamoxifen stimulates liver protein synthesis,
just like 17fl-oestradiol does, when given orally (Fahraeus et
al., 1982; Fex et al., 1981). Although our findings could also
be explained by decreased protein degradation, protein-
specific stimulation of production seems more likely. Our
data confirm and expand earlier data (Rossner & Wallgren,
1984), which showed that short term tamoxifen treatment
during 2 months, resulted in a decrease of LDL-C, hapto-
globin and orosomucoid, but an increase of a-antitrypsin
and ceruloplasmin. These findings and our own data are
compatible with a mild oestrogen-like effect.
Our observations could not be explained by changes in
body-weight, smoking, drinking habits, or the use of con-
comitant drugs, such as beta-blockers, tranquillizers or
barbiturates. Only 3 patients used beta-blockers and 14
women were using minor tranquillizers (mainly oxazepam)
throughout the observation period.
It is not clear why patients, who do not respond to
tamoxifen and who stop taking the drug after 2 to 3 months,
significantly differ from responding patients with regard to
HDL-C and HDL-C/total-C ratio as early as after 2 months
of tamoxifen. No such difference was observed for sex
hormone binding globulin or thyroxine binding globulin. It
seems therefore unlikely, that the lower HDL-C in the non-
responders can be explained by a lack of liver response to
tamoxifen, or by a less good patient compliance, leading to
inadequate tamoxifen intake and less tumour response.
Increased degradation of HDL-C may be an early sign of
failing therapy, which deserves further investigation.
The main conclusion from this study is that prolonged use
of tamoxifen is not likely to contribute to cardiovascular risk
by way of known serum lipoprotein risk factors.
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